Different types localisation of retinal fluid as prognostic biomarkers in the choice of anti-VEGF therapy for age-related macular degeneration

• Published in: Vestnik oftal'mologii Vol. 136; no. 6. Vyp. 2; p. 227
• Main Authors: Fursova, A Zh, Derbeneva, A S, Vasilyeva, M A, Tarasov, M S, Chubar, N V, Nikulich, I F
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2020
• Subjects: Aged; Angiogenesis Inhibitors - therapeutic use; Biomarkers; Choroidal Neovascularization - diagnosis; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Humans; Intravitreal Injections; Macular Degeneration - drug therapy; Prognosis; Ranibizumab - therapeutic use; Retina; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; anti-VEGF; subretinal fluid; intraretinal fluid; pigment epithelial detachment; optical coherence tomography
• ISSN: 0042-465X
• DOI: 10.17116/oftalma2020136062227

Age-related macular degeneration is an advanced chronic disease and the main cause of vision loss in geriatric patients. Optical coherence tomography (OCT) is a modern method of retinal imaging allowing to detect different types of fluid: intraretinal fluid (IRF), subretinal fluid (SRF) and fluid under pigment epithelial detachment (PED). Finding relevant imaging biomarkers is necessary for identification of basic activity criteria of the disease, choosing treatment algorithms, determining treatment duration and termination criteria, and predicting the outcomes. Presence of IRF is associated with poor functional outcomes. Its presence is an indication for early beginning of treatment aimed at full resorption of the fluid with further possible careful extension of anti-VEGF therapy intervals with a regular follow-up. Degenerative intraretinal cysts developing in the background of subretinal fibrosis in absence of choroidal neovascularization (CNV) should be a sign for discontinuation of anti-VEGF therapy due to the lack of targets. Presence of SRF is associated with favorable outcomes and good treatment prognosis and is not a barrier to the extension of treatment intervals even up to the maximum of 16 weeks as described in existing randomized controlled trials, on the condition of no other CNV activity. PED with active CNV is one of the biomarkers that reveal the need for long-term aggressive therapy. In case of its size gain, it is necessary to restart the anti-VEGF treatment to prevent visual loss in the long-term. Combination of different fluid types is a sign of lasting disease history with a poor outcome prognosis. In this case, anti-VEGF treatment should be started as soon as possible with long-term fixed regimen or Treat-and-extend (T&E) with minimal suitable interval for the patient and precise monitoring of the condition of retina until complete suppression of activity. Developing a personalized approach in each case plays an important role in preserving visual functions.